Please type a plus sign (+) inside this box	 4
i lease type a plus sign (+) inside this box	 

Hak

That that then

4 J.,, b A. PTO/SB/01 (10-00) Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Attorney Docket Number **DECLARATION FOR UTILITY OR** First Named Inventor Nadia Malouf **DESIGN** PATENT APPLICATION COMPLETE IF KNOWN (37 CFR 1.63) **Application Number** Filing Date ☐ Declaration Submitted after Initial ■ Declaration OR Submitted Group Art Unit Filing (surcharge (37 CFR 1.16 (e)) with Initial Filing **Examiner Name** required)

As a below named inventor, I hereby declare that:					
My residence, mailing address, an	d citizenship are as sta	ated below next to my na	ame.		
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:  PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME					
		Title of the Invention)	IETHODO OPT	NG DAPIE	
the specification of which	ι-	no or are invention,			
is attached hereto					
was filed on (MM/DD/YYYY)		as United :	States Application	Number or PCT International	
Application Number (if applicable).					
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.					
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.					
I hereby claim foreign priority benefits under 35 U S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.					
Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)		Certified Copy Attached? YES NO	
Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:					
I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.					
Application Number(s)	Filing Date	e (MM/DD/YYYY)	Additional provisional application		
60/258,169	12/22/	2000	numbers suppleme	are listed on a ental priority data sheet 02B attached hereto.	

[Page 1 of 2]
Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

THE STATE SHEET SH

78

## **DECLARATION** — Utility or Design Patent Application

Direct all correspondence to:	Customer N or Bar Code				OR 🗌	Correspondence	address below
Name PATENT TRADEMARK OFFICE							
Address							
Address			· · · · · · · · · · · · · · · · · · ·	<del></del>			
City				State		ZIP	
Country		Telephor	ne			Fax	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.							
NAME OF SOLE OR FIRST INV	ENTOR :			A peti	ition has been fil	ed for this uns	igned inventor
Given Name (first and middle [if any]) Nadia Family Name or Surname Malouf							
Inventor's Signature			7-			Date	
Residence: City Durham			State	NC	Country USA	Citizenship	USA
Mailing Address 13 Surrey Lane							
Mailing Address							
City Durham	State	NC		ZIP	27707	Country	USA
NAME OF SECOND INVENTOR	•			A peti	tion has been fil	ed for this uns	igned inventor
Given Name (first and middle [if any]) <b>Timothy</b>	C.	···		Family or Surr		ols	
Inventor's Signature						Date	
Residence: City Chapel Hill			State	NC	Country USA		ПО
Mailing Address 322 Ferguson Road							
Mailing Address							
City Chapel Hill  ☐ Additional inventors are being named	State No			<b>ZIP</b> nal Inven	<b>27514</b> ator(s) PTC	Country /SB/02A attached	USA I hereto.
			·				



Atty Docket: 421/29

## <u>ASSIGNMENT</u>

WHEREAS, we, Nadia Malouf, City of Durham, State of North Carolina, and Timothy C. Nichols, City of Chapel Hill, State of North Carolina (hereinafter "Assignors"), have invented certain new and useful improvements in PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME for which an application for Letters Patent of the United States was made on December 22, 2000 as U.S. Provisional Patent Application Serial No. 60/258,169.

AND, WHEREAS, The University of North Carolina, a non-profit organization located at Chapel Hill, North Carolina (hereinafter "Assignee"), is desirous of acquiring an interest therein.

NOW, THEREFORE, To Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors have sold and by these presents do hereby sell, assign, transfer and convey unto the said Assignee, its successors and assigns, his/her or their entire right, title and interest in and to said invention and application, and in and to any and all United States patent applications filed pursuant to 35 U.S.C. § 111(a) pertaining to said invention and/or which claim priority to the United States provisional patent application referenced above, and in and to any and all continuations, continuations-in-part, or divisions of any U.S. or foreign patent application filed on the invention, and in and to any and all Letters Patent of the United States of America and all foreign countries or reissues or extensions thereof which may be granted therefor or thereon, for the full end of the term for which said Letters Patent may be granted, together with his/her or their right to claim the priority of said application in all foreign countries in accordance with the International Convention, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignors if this assignment and sale had not been made.

Assignors hereby request that said Letters Patent be issued in accordance with this assignment.

Assignors further covenant and agree that, at the time of the execution and delivery of these presents, Assignors possess full title to the invention and application abovementioned, and that they have the unencumbered right and authority to make this assignment.

Assignors further covenant and agree, and likewise bind their heirs, legal representatives and assigns, to promptly communicate to said Assignee or its representatives any facts known to them relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the Assignee, its representatives, successors and assigns to secure patent or similar protection for the said invention in all countries and to vest in the Assignee complete title to the said invention and Letters Patent, without further compensation, but at the expense of said Assignee, its successors, assigns and other legal representatives.

_	- •				
Executed	d this 21	day of _	March		2001.
Witnessed by:			Nadia Ma		
Marke Name	R Worden	3/- Date	u/01		
Name		Date			
		* * * * *	* * * * *		
Executed	d this $2/$ da	y of	March	L	2001.
			Tundy Timothy (	M D. Nichols	Victor
Witnessed by:		•		<i></i>	
Name cm	M 60 dro MESSION EXP 5/12/	راجه/ <u>ک</u> مgate	la		
Name		Date			

**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Malouf et al.

Group Art Unit: Not Assigned

**Serial No.: Not Assigned** 

Examiner: Not Assigned

Filed: Herewith

Docket No.: 421/29/2

Confirmation No.: Not Assigned

For: PURIFIED AND ISOLATED PLATELET CALCIUM CHANNEL NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS

**USING SAME** 

STATEMENT THAT SEQUENCE LISTING AND COMPUTER READABLE COPY ARE THE SAME

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821(f), applicants hereby state that the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing on paper.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: 12-20-0

Ву:

Arles A. Taylor, Jr. 18 Registration No. 39,395

Suite 1400 University Tower 3100 Tower Boulevard Durham, North Carolina 27707 Telephone: (919) 493-8000 Facsimile: (919) 419-0383

Customer No. Bar Code Label:

421/29/2

AAT/ajm

25297